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Abstract 
We describe the case of a patient who pre-
sented with a right-sided glomus jugulare
tumor and bilateral glomus vagale tumors.
These proved to be nonmalignant paragan-
gliomas on histopathological analysis. Genetic
analysis revealed a germline heterozygous
missense mutation (Pro81Leu) in the succi-
nate dehydrogenase subunit D (SDHD) gene.
We discuss the clinical presentations of the
familial paraganglioma syndrome type 1,
which is caused by mutations in SDHD, and
the implications for the clinical diagnosis and
care of such patients.
Case Report
A 35-year old lady presented with right-
sided pulsatile tinnitus, conductive deafness,
and a vascular lesion in the floor of the right
external auditory meatus. Magnetic reso-
nance imaging revealed a right-sided glomus
jugulare tumor and bilateral glomus vagale
tumors (Figure 1). Both her paternal grandfa-
ther and her father had undergone neck sur-
gery for tumors. She was an only child and had
a two-year-old son. She was normotensive,
with no clinical features of von Hippel-Lindau
(VHL) syndrome or neurofibromatosis type 1
(NF1). Serum calcium, urine catecholamine
excretion, and serum calcitonin were within
normal limits. Radiolabeled metaiodobenzyl-
guanidine scanning and MRI imaging of her
abdomen did not demonstrate any intra-
abdominal paragangliomas. She underwent
partial excision of her right glomus jugulare
tumor, with complete excision of both the glo-
mus vagale tumors. Histology showed nonma-
lignant paragangliomas. Genomic DNA analy-
sis revealed a germline heterozygous mis-
sense mutation (p.Pro81Leu) in exon 3 of the
succinate dehydrogenase subunit D (SDHD)
gene. Therefore she was diagnosed with
familial paraganglioma syndrome type 1
(PGL1). 
Discussion
Paragangliomas are neuroendocrine
tumors of the autonomic nervous system.
Abdominal and thoracic paragangliomas are
derived from sympathetic tissue and secrete
catecholamines, like pheochromocytomas,
which are derived from the adrenal medulla.
Head and neck paragangliomas are derived
from parasympathetic tissue and usually do
not secrete catecholamines.1 Up to a third of
paragangliomas and pheochromoctyomas are
associated with hereditary causes; i.e., muta-
tions in VHL, RET (causing multiple endo -
crine neoplasia type 2A-MEN2A), NF1, and the
SDH complex genes SDHB, -C and -D.2
The SDH complex is bound to the inner
mitochondrial membrane and participates in
both the electron-transport chain and the
Krebs cycle as part of complex II. It consists of
four subunits A-D. Mutations in subunits B, C,
and D are associated with hereditary
pheochromocytomas and paragangliomas: the
PGL1 syndrome with mutations in SDHD,
PGL3 with mutations in SDHC, and PGL4 with
mutations in SDHB.
Multiple mechanisms have been implicated
in the pathogenesis of SDH subunit-related
tumors. These include abnormal activation of
hypoxia-inducible pathways, producing a
pseudohypoxic state similar to that seen in
tumors from patients with VHL disease.3,4 The
HIF-1 and HIF-2 transcription factors are
major mediators of the hypoxic gene response
and the HIF-α subunits are rapidly degraded
in normoxic cells via a VHL protein (pVHL)-
dependent mechanism.5 Activation of HIF
pathways with SDH subunit inactivation has
been linked to accumulation of succinate and
resulting inhibition of the prolyl hydroxylase
enzymes that are necessary for HIF-α subunit
modification and proteosomal degradation, as
pVHL is unable to bind the unmodified sub-
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Figure 1. Magnetic resonance
image scan of the neck. Fast
T2-weighted MRI scan
demonstrates the right glomus
jugulare tumor (adjacent to
right cochlea, arrow), and
bilateral glomus vagale tumors
(arrows).
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units.4 In addition, animal models of SDH
inactivation suggest that reactive oxygen
species may be increased and also might pro-
voke a pseudohypoxic state.6 Therefore
SDHB/D mutations may predispose to a failure
of normal developmental apoptosis of sympa-
thetic neuronal cells leading to persistence of
“pheochromocytoma precursor cells”.5 PGL1/
SDHD disease is inherited as an autosomal
dominant trait, but demonstrates parent-of-
origin effects in that tumors only develop
when the mutation is inherited from the
father, with possible rare exceptions.6
Typically, head and neck paragangliomas are
found, but pheochromocytomas and abdomi-
nal or thoracic paragangliomas can develop
also. The tumors often are multiple, and tend
to develop early, with a median age of first
presentation of 31 years. In addition, there is
an age-dependent penetrance, with 48 per-
cent, 73 percent, and 100 percent being diag-
nosed by the ages of 30, 40, and 70 years,
respectively.7 In contrast to PGL4/SDHB dis-
ease, where metastatic disease is common,
the tumors in PGL1 tend to be benign.7
Conclusions
The clinical data accumulated regarding
familial paraganglioma syndromes raise sev-
eral important implications for their clinical
management.
• Firstly, patients with familial disease or
multiple tumors should be offered genetic
testing. In addition, individuals with
apparently sporadic pheochromocytoma or
paraganglioma disease will require genetic
screening if risk factors such as extra-
adrenal sympathetic paraganglioma,
malignant paraganglioma, or young age at
diagnosis (e.g., below 40 years) are pres-
ent.2 Depending on the clinical presenta-
tion, mutation analysis of VHL, SDHB,
SDHC, SDHD, and/or RET genes may be
indicated. 
• Secondly, the relatives of patients in whom
a pathogenic mutation is detected should
be offered genetic screening, even if they
are asymptomatic, because of the age-
dependent penetrance. The inheritance
pattern of PGL1-related disease will influ-
ence the screening program (see follow-
ing) and the counseling given to patients
and their relatives. In our patient’s case,
her son is not likely to develop tumors
because of the parent-of-origin effect on
penetrance. However, he will require
genetic screening when he is older,
because if he is a carrier of the SDHD
mutation, then his children may be at risk. 
• Thirdly, carriers of these mutations will
require regular, lifelong, clinical, biochem-
ical, and radiological screening. In order to
reduce the lifetime exposure to ionizing
radiation, it is necessary to use imaging
modalities such as MRI or ultrasound.
Optimum clinical management requires
the multidisciplinary expertise of sur-
geons, endocrinologists, clinical geneti-
cists, and radiologists.
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